Loading...
 
Mediterr J Rheumatol 2017;28(3):133-41
The effect of non-steroidal anti-inflammatory drugs on matrix metalloproteinases levels in patients with osteoarthritis
Authors Information

A.H.E.P.A. Hospital/First Internal Medicine Clinic, Thessaloniki, Greece

References
  1. Feldson D T, Zhang Y. An update on epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheumatol 1998;41:1343-55.
  2. Kuttner K, Goldberg V M. Osteoarthritis disorders. American Academy of Orthopaedic Surgeons. Rosemont 1995, XXI-V.
  3. Martel-Pelletier J, Welsch D J, Pelletier J P. Metalloproteases and inhibitors in arthritic diseases. Best Pract Res Clin Rheumatol 2001;15:805-29.
  4. Poole A R, Howell D S, Etiopathogenesis of Osteoarthritis. In: Moskowitz R W, Howell D S, Goldberg V M, Mankin J H (eds). Osteoarthritis: Diagnosis and Management. 3rd ed. Philadelphia: Saunders, 2001;29-47.
  5. Shlopov B V, Lie W-R, Mainardi C L, Cole A A, Chubinskaya S, Hasty K A. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum 1997;40:2065-74.
  6. Freemont A J, Hampson V, Tilman R, Goupille P, Taiwo Y, Hoyland J A. Gene expression of matrix metalloproteinase 1, 3 and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific. Ann Rheum Dis 1997;56:542-9.
  7. Tetlow L C, Adlam D J, Wooley DE. Matrix metalloproteinase and Proinflammatory Cytokine production by chondrocyte of human osteoarthritic cartilage. Arthritis Rheum 2001;44:585-94.
  8. Nagase H, Woessner J F, Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21791-4.
  9. Madlener M, Parks W C, Werner S. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during escisional skin wound repair. Exp Cell Res 1998;242:201-10.
  10. Shapiro S D. Matrix metalloproteinases degradation of extracellular matrix biological consequences. Curr Opin Cell Biol 1998;10:602-8.
  11. Moldovan F, Pelletier J P, Hambor J, et al. Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritis cartilage in site: In vitro micking effects by transforming growth factor beta. Arthritis Rheum 1997;40:1053-61.
  12. Martel-Pelletier J. Pathophysiology of osteoarthritis. Osteoarthritis cartilage 1998;6:374-6.
  13. Pelletier J P, Martel-Pelletier J, Howell D S. Etiopathogenesis of osteoarthritis. In: Koopman WJ (ed). Arthritis and Allied Conditions. A Textbook of Rheumatology. 13rd ed. Baltimore: Williams and Wilkins 1997;1969-84.
  14. Van de Loo F A, Joosten L A, Van Lent P L, Arntz O J, Van Den Berg W B. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen and zymosan induced arthritis. Arthritis Rheum 1999;38:164-72.
  15. Gearing A J, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson A H, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370:555-7.
  16. Lepuesne M, Brandt K, Bellamy N, Moskowitz R, Menkes CJ, Pelletier JP. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 1994;21:65-73.
  17. Brady S J, Brooks P, Canaghan P, Kenyon L M. Pharmacotherapy and osteoarthritis. In: Bellamy N (ed). Baillere’s Clinical Rheumatology. London: Baillére Tindall; 1997:749-68.  
  18. Brandt K O. Toward pharmacologic modification of joint damage in osteoarthritis. Ann Intern Med 1995;122:874-5.
  19. Dingle J T, Parker M. NSAID stimulation of human cartilage matrix synthesis. Clin Drug Invest 1997;14:353-62.
  20. Pelletier J P. The influence of tissue cross-taking on OA progression: Role of nonsteroidal antiinflammatory drugs. Osteoarthritis Cartilage 1999;7:374-6.
  21. Ding C H. Do NSAIDS affect the progression of osteoarthritis? Inflammation 2002;26:139-42.
  22. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
  23. Altman R. Classification of disease: Osteoarthritis Semin Arthritis Rheum 1991;20:40-7.
  24. Altman R, Alarcon G, Appelrough D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601-10.
  25. Altman R, Alarcon G, Appelrough D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34:505-14.
  26. Kellgren J H, Lawrence J S. Radiologic assessment of osteoarthrosis. Ann Rheum Dis 1957;16:494-501.
  27. Hochberg M C, Chang R W, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1991;35:498502.
  28. Altman R, Asch E, Bloch D, Bale G, Borenstein D, Brandt K. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
  29. Poole A R, Kobayashi M, Yasuda T, Laverty S, Mwale F, Kojima T, et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis 2002;61: ii78-ii81.
  30. Van Den Berg W B. Lesson from animal models of osteoarthritis. Curr Opin Rheumatol 2001;13:452-6.
  31. Mouritzen U, Christgau S, Lehmann H J, Tankd L B, Christiansen C. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis 2003;62:332-6.
  32. Garnero P, Charni N, Juillet F, Conrozier T, Vignon E. Increased urinary type II collagen helical and C telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 2006;1639-44.
  33. Naito K, Takahashi M, Kushida K, Suzuki M, Ohishi T, Miura M, et al. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: Comparison with generalized osteoarthritis. Rheumatology 1999;38:510-15.
  34. Yamamaka H, Matsuda Y, Tanaka M, et al. Serum matrix metalloproteinase 3 as a predictor of a degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-8.
  35. Burgkart R, Glaser C, Hyhlik-Durr A, Englmeir K H, Reiser M, Eckstein F. Magnetic resonance imaging-based assessment of cartilage loss in severe osteoarthritis: accuracy, precision, and diagnostic value. Arthritis Rheum 2001;44:20072-7.
  36. Simon L S. Nonsteroidal anti-inflammatory drugs. In: Klippel J H (ed). Primer on the Rheumatic Diseases. Atlanta Georgia: Arthritis Foundation 2001:583-91.
  37. Feldman M, McMabon A T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132:134-41.
  38. Mastbergen S C, Lafeber F P, Bijlsma J W. Selective COX-2 inhibition prevents proinflammatory cytokine-induced cartilage damage. Rheumatology (Oxford) 2002;41:801-8.
  39. El Hajjaji H, Marcelis A, Devogelaer J P, Manicourt D H. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritis cartilage. J Rheumatol 2003;30:2444-51.
  40. Sanchez C H, Mateus M M, Defresne M P, Crieland J M, Reginster J Y, Henrotin Y. Metabolism of human articular chondrocyte. Cultured in alginate beads-longterm effects of Interleukin 1β and Non-steroidal Antiinflammatory Drugs. J Rheumatol 2002;29:772-82.
  41. Tindall E A, Sharp J T, Burr A, Kotz T K, Wallemark C B, Verbung K, et al. A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib. Clin Ther 2002;24:2051-63.
  42. Nagase H. Activation mechanisms of matrix metalloproteinases. J Biol Chem 1997;378:151-60.
  43. Yoshihara Y, Nakamura H, Obata K, Harumoto Y, Hayakawa T, Fujikawa K, Okada Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 2000;59:455-61.
  44. Tchetverikov I, Lard L R, DeGroot J, Verzijll N, Tekoppele J M, Breedveld F C, Huizinga T W, Hanemaaijer R. Matrix metalloproteinase -3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003;62:1094-99.
  45. Sadowski T, Steinmeyer J. Effects on non-steroidal antiinflammatory drugs and dexamethesone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. Osteoarthritis Cartilage 2001;9:407-15.
  46. Blot L, Marcelis A, Devogelaer J P, Manicourt D P. Effects of diclofenac, aceclofenac and meloxicam on metabolism of proteoglycans and hyaluronan in osteoarthritis human cartilage. Br J Pharmacol 2000;131:1413-21.
  47. Dingle J T, Parker M. NSAID Stimulation of human cartilage matrix synthesis. Clin Drug Invest 1997;14:353-62.
  48. Gonzales E, De la Cruz C, De Nicolas R, et al. Long term effects of NSAID on the production of cytokines and other inflammatory mediators by blood cells of patients with OA. Agents Action, 1994;171-8.
  49. Akimoto H, Yamaraki R, Hashimoto S, Sato T, Ito A. 4’ hydroxy aceclofenac suppresses the interleukin-1 induced production of promatrix metalloproteinases and release of sulfated glycosaminoglycans from rabbit articular chondrocytes. Eur J Pharmacol 2000;11:429-36.